Takeda Pharmaceutical Co. said its blood plasma-derived therapy against coronavirus currently in development has the potential to be among the first approved treatments for the deadly pathogen.
The Japanese pharmaceutical company could have an edge because the treatment involves a process that already has approval from regulators. The key point in negotiations with regulators for approval is whether it has the necessary concentration of the antibody, or titer, needed to fight the Covid-19 disease, said Julie Kim, Zurich-based president of Takeda’s plasma-derived therapies unit.
#COVID-19 #infectious diseases #BioExcel